Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial
Nephrology Dialysis Transplantation | February 18, 2017 | Volume: 33 | Issue: 3 | Pages: 477-489
10.1093/ndt/gfx043
| PMID 28379536